Moderna, Inc. reported revenue of $0.14B for the period ended 2026-06-30, +2.1% year on year. Net income was $-0.78B, a -539.3% net margin on a 35.9% gross margin. The largest revenue line is COVID19 at 63% of the total. Free cash flow for the period was $-0.56B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.14B | +2.1% |
| Gross profit | $0.05B | — |
| Operating income | $-0.81B | — |
| Net income | $-0.78B | — |
| Gross margin | 35.9% | Net margin -539.3% |
| Revenue Q/Q | -62.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| COVID19 | $0.09B | 62.8% |
| Stand Ready Manufacturing | $0.03B | 21.4% |
| Collaboration Arrangement Including Arrangements With Affiliate | $0.01B | 10.3% |
| RSV | $0.00B | 2.1% |
| License And Royalty | $0.00B | 2.1% |
| Grant | $0.00B | 1.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.09B | 64.1% |
| R&D | $0.65B | 449.0% |
| SG&A | $0.22B | 149.0% |
| Tax & other | $-0.03B | -22.8% |
| Item | Amount |
|---|---|
| Total assets | $10.96B |
| Total liabilities | $4.20B |
| Shareholders' equity | $6.76B |
| Equity / assets | 61.7% |
| Operating cash flow | $-0.53B |
| Capital expenditure | $0.04B |
| Free cash flow | $-0.56B |
| Cash conversion (OCF / net income) | 67% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
TAP ・ MDLZ ・ MPWR ・ MNST ・ MCO ・ MS ・ MOS ・ MSI ・ MSCI ・ NDAQ ・ NTAP ・ NFLX
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies